Lianne Barnieh

EE713 The Impact of Delaying Access to Innovative Therapies in Emerging Markets for Chronic Lymphocytic Leukemia: A Modeling Study

Talha Munir, Shilpi Swami, R Lakshmi, Lianne Barnieh et autres

gb (code pays fourni par la source)

Number of cardiac deaths associated with ibrutinib versus zanubrutinib for the treatment of chronic lymphocytic leukemia: A European risk-based estimation

Talha Munir, Paolo Sportoletti, Andrea Visentin, Leyla Mohseninejad et autres

Abstract Introduction Bruton tyrosine kinase inhibitors include ibrutinib (first generation) and zanubrutinib (next-generation) are approved treatments of chronic lymphocytic leukemia (CLL) in the EU. They have demonstrated efficacy as monotherapy for the treatment of CLL in the first-line (1L) setting (zanubrutinib in …

gb, it, py, us, es, fr (code pays fourni par la source)

Number of patients needed to treat to prevent one atrial fibrillation event with zanubrutinib versus ibrutinib and acalabrutinib in B-cell malignancies

Talha Munir, Paolo Sportoletti, Leyla Mohseninejad, Lianne Barnieh et autres

Abstract Introduction Bruton tyrosine kinase inhibitors (BTKis) are used for the treatment of B-cell malignancies. Second generation (acalabrutinib) and next generation (zanubrutinib) BTKis have demonstrated improved cardiovascular safety profiles compared to first-generation BTKi, ibrutinib. A recent systematic review and network meta-analysis of …

gb, it, py, fr (code pays fourni par la source)

Indirect comparison of efficacy of zanubrutinib vs ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma

Toby Andrew Eyre, Leyla Mohseninejad, Lianne Barnieh, Kaijun Wang et autres

Abstract Introduction: Mantle cell lymphoma (MCL) is an aggressive and rare form of non-Hodgkin lymphoma, with nearly all patients eventually relapsing after initial treatment. Covalent Bruton tyrosine kinase (BTK) inhibitors, including the first-generation inhibitor ibrutinib, the second-generation inhibitor acalabrutinib and the next-generation …

gb, py (code pays fourni par la source)

Landscape and Heterogeneity of Treatment Outcome Measures in Facioscapulohumeral Muscular Dystrophy: A Systematic Literature Review

Katy J. Eichinger, Lianne Barnieh, Rachel Beckerman, Adi Eldar‐Lissai

Abstract Facioscapulohumeral muscular dystrophy is a rare genetic disorder that manifests as progressive weakening and loss of skeletal muscles, with the face, shoulder girdle, and upper arms typically affected in early stages. Currently, there are no approved therapies, and no consensus on …

us (code pays fourni par la source)

535 | A MULTI‐COUNTRY ANALYSIS OF THE COST OF MANAGING ADVERSE EVENTS IN CHRONIC LYMPHOCYTIC LEUKEMIA

John Thomson, Lianne Barnieh, Leyla Mohseninejad, Marco Aurélio Salvino

Introduction: Identifying the optimal treatment choice in chronic lymphocytic leukemia (CLL) can pose challenges for clinicians.The approval of, and access to, new treatments play a major role in treatment selection.In addition to efficacy, adverse events (AEs) and the cost of managing AEs …

Afrique du Sud, br (code pays fourni par la source)

The Flow of Living Kidney Donor Candidates Through the Evaluation Process: A Single-Center Experience in Ontario, Canada

Steven Habbous, Beth Montesi, Corinne Weernink, Sisira Sarma et autres

Introduction: Tracking the evaluation process of living kidney donor candidates facilitates benchmarking and can inform process redesign to improve experiences with the evaluation and enable more living donor kidney transplantation. Methods: We reviewed the medical records for all living donor candidates who …

ca (code pays fourni par la source)

SA74 A Systematic Literature Review to Assess the Level of Evidence in Facioscapulohumeral Muscular Dystrophy

Lianne Barnieh, Robert C. Beckerman, H. Emich, Katy J. Eichinger et autres

Lessons learned from the Alberta Border Testing Pilot Program

Jaling Kersen, Tayler Dawn Scory, Oluwasefunmi Akeju, Robert G. Weaver et autres

Background: During the Coronavirus disease (COVID-19) pandemic, countries implemented border control and quarantine measures to reduce transmission. The Alberta Border Testing Pilot Program (ABTPP) allowed international travellers entering Alberta to reduce their quarantine period following two negative COVID-19 tests. We evaluated participant …

ca (code pays fourni par la source)

P314 A systematic literature review to assess the level of evidence in facioscapulohumeral muscular dystrophy

Lianne Barnieh, Robert C. Beckerman, H. Emich, Katy J. Eichinger et autres

us (code pays fourni par la source)

The cost-effectiveness of non-invasive stool-based colorectal cancer screening offerings from age 45 for a commercial and medicare population

Derek Ebner, John B. Kisiel, Lianne Barnieh, Rishika Sharma et autres

Aim: The United States Preventive Services Taskforce (USPSTF) recently recommended lowering the age for average-risk colorectal cancer (CRC) screening from 50 to 45 years.While initiating screening at age 45 versus 50 provides a greater opportunity for CRC early detection and prevention, the …

us (code pays fourni par la source)

Cost-effectiveness analysis of HIV pre-exposure prophylaxis in Japan

Daisuke Mizushima, Yoshino Nagai, Dylan J. Mezzio, Keisuke Harada et autres

BACKGROUND: While global efforts have been made to prevent transmission of HIV, the epidemic persists. Men who have sex with men (MSM) are at high risk of infection. Despite evidence of its cost-effectiveness in other jurisdictions, pre-exposure prophylaxis (PrEP) for MSM is …

jp, us (code pays fourni par la source)